Develop and commercialize branded and generic pharmaceuticals. Offer a range of nutraceutical products. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $65.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 29 buys and 7 sells. Management buying with its own money is usually read as a good sign.
A loss of $19.1M against $65.3M in annual sales.
The stock sits at $0.25. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, COSM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: COSM is a high-risk stock — not yet profitable, and its future rides on its product catching on.